Browsing ICR Divisions by author "Rabbitts, Terence"
Now showing items 21-28 of 28
-
Multimeric antibodies with increased valency surpassing functional affinity and potency thresholds using novel formats.
Miller, A; Carr, S; Rabbitts, T; Ali, H (TAYLOR & FRANCIS INC, 2020-01-01)The success of therapeutic antibodies is largely attributed for their exquisite specificity, homogeneity, and functionality. There is, however, a need to engineer antibodies to extend and enhance their potency. One parameter ... -
Pan RAS-binding compounds selected from a chemical library by inhibiting interaction between RAS and a reduced affinity intracellular antibody.
Tanaka, T; Thomas, J; Van Montfort, R; Miller, A; Rabbitts, T (NATURE PORTFOLIO, 2021-01-18)Intracellular antibodies are valuable tools for target validation studies for clinical situations such as cancer. Recently we have shown that antibodies can be used for drug discovery in screening for chemical compounds ... -
Salmonella-based platform for efficient delivery of functional binding proteins to the cytosol.
Chabloz, A; Schaefer, JV; Kozieradzki, I; Cronin, SJF; Strebinger, D; et al. (NATURE PUBLISHING GROUP, 2020-07-03)Protein-based affinity reagents (like antibodies or alternative binding scaffolds) offer wide-ranging applications for basic research and therapeutic approaches. However, whereas small chemical molecules efficiently reach ... -
Selection and Characterization of a Nanobody Biosensor of GTP-Bound RHO Activities.
Keller, L; Bery, N; Tardy, C; Ligat, L; Favre, G; et al. (MDPI, 2019-01-09)RHO (Ras HOmologous) GTPases are molecular switches that activate, in their state bound to Guanosine triphosphate (GTP), key signaling pathways, which involve actin cytoskeleton dynamics. Previously, we selected the nanobody ... -
Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment.
Quevedo, CE; Cruz-Migoni, A; Bery, N; Miller, A; Tanaka, T; et al. (NATURE PORTFOLIO, 2018-08-09)Targeting specific protein-protein interactions (PPIs) is an attractive concept for drug development, but hard to implement since intracellular antibodies do not penetrate cells and most small-molecule drugs are considered ... -
Structural and functional characterization of a DARPin which inhibits Ras nucleotide exchange.
Guillard, S; Kolasinska-Zwierz, P; Debreczeni, J; Breed, J; Zhang, J; et al. (NATURE PUBLISHING GROUP, 2017-07-14)Ras mutations are the oncogenic drivers of many human cancers and yet there are still no approved Ras-targeted cancer therapies. Inhibition of Ras nucleotide exchange is a promising new approach but better understanding ... -
Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds.
Cruz-Migoni, A; Canning, P; Quevedo, CE; Bataille, CJR; Bery, N; et al. (NATL ACAD SCIENCES, 2019-02-12)The RAS gene family is frequently mutated in human cancers, and the quest for compounds that bind to mutant RAS remains a major goal, as it also does for inhibitors of protein-protein interactions. We have refined ... -
Surfaceome interrogation using an RNA-seq approach highlights leukemia initiating cell biomarkers in an LMO2 T cell transgenic model.
Pais, H; Ruggero, K; Zhang, J; Al-Assar, O; Bery, N; et al. (NATURE PUBLISHING GROUP, 2019-04-08)The surfaceome is critical because surface proteins provide a gateway for internal signals and transfer of molecules into cells, and surfaceome differences can influence therapy response. We have used a surfaceome analysis ...